The role of I2BS in Parkinson’s disease
Research type
Research Study
Full title
Imidazoline-2 Binding Site as a novel neuroinflammatory target in Parkinson’s disease: An [11C]BU99008 Positron Emission Tomography study
IRAS ID
201181
Contact name
Marios Politis
Contact email
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Astrocytes are cells in the brain that are activated in response to injury of the neurons and are involved in a process called neuroinflammation. Imidazoline-2 binding sites (I2BS) are expressed during the activation of astrocytes. We have now developed a ligand called [11C]BU99008 which is used together with positron emission tomography (PET) and can measure I2BS in the brain and therefore assess the presence of neuroinflammation in the human brain including in people with Parkinson’s disease.
In this study we hypothesize that neuroinflammation is a critical process underlying the development of Parkinson’s disease and activation of astrocytes plays a key role. We believe that I2BS will be overexpressed in the brain of people with Parkinson’s disease and will reflect substantial activation of astrocytes and therefore neuroinflammation.
Each patient will receive one [11C]BU99008 PET scan and one 3-Tesla MRI scan:
Group A: up to 30 PD patients
Group B: up to 30 aged and gender matched healthy controls.REC name
London - Hampstead Research Ethics Committee
REC reference
16/LO/0638
Date of REC Opinion
21 Apr 2016
REC opinion
Further Information Favourable Opinion